{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"methotrexate-associated-lymphoproliferative-disorders","columns":[],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":[],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":[],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"not available","narrativeSourceChanges":[],"records":0,"sourceGroups":{}},"features":[],"ledeHtml":"Methotrexate-associated lymphoproliferative disorders are rare immunodeficiency-associated lymphoproliferative diseases characterized by lymphoid proliferation or lymphomas (large B-cell lymphoma, T-cell lymphoma, Hodgkin lymphoma, reactive lymphadenitis and a polymorphic post-transplant lymphoproliferative disorder) that develop in patients with different autoimmune diseases treated with methotrexate. Swelling is the predominant manifestation of the disease and regression after methotrexate withdrawal is observed in a significant proportion of patients.","mondoId":"MONDO:0019483","node":{"canonicalSlug":"methotrexate-associated-lymphoproliferative-disorders","comparisons":[],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"definition-only","matchMethod":"same-ontology-node","name":"methotrexate-associated lymphoproliferative disorders","paragraphs":["Methotrexate-associated lymphoproliferative disorders are rare immunodeficiency-associated lymphoproliferative diseases characterized by lymphoid proliferation or lymphomas (large B-cell lymphoma, T-cell lymphoma, Hodgkin lymphoma, reactive lymphadenitis and a polymorphic post-transplant lymphoproliferative disorder) that develop in patients with different autoimmune diseases treated with methotrexate. Swelling is the predominant manifestation of the disease and regression after methotrexate withdrawal is observed in a significant proportion of patients."],"scope":"exact","source":"MONDO","upstream":"Orphanet:86904","url":"https://monarchinitiative.org/MONDO:0019483"},"ownColumnKeys":[],"publication":"published","relationships":[{"kind":"parent","label":"lymphoma","mondoId":"MONDO:0005062","slug":null},{"kind":"parent","label":"immunodeficiency-associated lymphoproliferative disease","mondoId":"MONDO:0020083","slug":null}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[{"reason":"Public source record is not available in the frozen inputs","source":"GARD","url":"https://rarediseases.info.nih.gov/diseases/19083"}],"translation":"published"},"records":[],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0019483\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>definition-only</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>same-ontology-node</dd><dt>Upstream attribution</dt><dd>Orphanet:86904</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Methotrexate-associated lymphoproliferative disorders are rare immunodeficiency-associated lymphoproliferative diseases characterized by lymphoid proliferation or lymphomas (large B-cell lymphoma, T-cell lymphoma, Hodgkin lymphoma, reactive lymphadenitis and a polymorphic post-transplant lymphoproliferative disorder) that develop in patients with different autoimmune diseases treated with methotrexate. Swelling is the predominant manifestation of the disease and regression after methotrexate withdrawal is observed in a significant proportion of patients.</p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0019483\" rel=\"noreferrer\">MONDO</a></p>","key":"overview","title":"Brief description"}],"sharedSources":[],"slug":"methotrexate-associated-lymphoproliferative-disorders","sourceDocuments":[{"name":"MONDO: methotrexate-associated lymphoproliferative disorders","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0019483"}],"sourceNote":"","synonyms":["methotrexate-associated lymphoproliferation","methotrexate-associated lymphoproliferative disorder","MTX-associated lymphoproliferative disorders","MTX-LPD"],"takeawayHtml":"","title":"methotrexate-associated lymphoproliferative disorders"},"schemaVersion":1}
